3-(5-Dimethylamino-1-naphthalenesulphonyl)-2-(3-pyridyl)thiazolidine

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 3-(5-Dimethylamino-1-naphthalenesulphonyl)-2-(3-pyridyl)thiazolidine
• 英文别名: N,N-dimethyl-5-[(2-pyridin-3-yl-1,3-thiazolidin-3-yl)sulfonyl]naphthalen-1-amine
• 化学式: C₂₀H₂₁N₃O₂S₂
• 分子量: 399.5
• InChiKey: OQGUMBDUTXYKCO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  87.2
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• Methods and compositions for modulating drug activity through telomere damage
  申请人：Au L.-S. Jessie

  公开号：US20060128651A1

  公开（公告）日：2006-06-15

  The invention provides methods and compositions for modulating the activity of therapeutic agents for the treatment of a cancer by administering one or more agents that (either alone or in combination) induces telomere damage and inhibits telomerase activity in the cancer cell. The method initially uses, e.g., a telomere damage-inducing agent such as paclitaxel, and a telomerase inhibitory agent such as AZT. The invention also provides methods for identifying other agents with telomere damage-inducing activity and/or telomerase inhibitory activity (as well as and compositions having such activity), for use in the treatment of cancer.

  本发明提供了通过施用一种或多种（单独或联合）诱导端粒损伤和抑制癌细胞端粒酶活性的制剂来调节治疗癌症的制剂活性的方法和组合物。该方法最初使用端粒损伤诱导剂（如紫杉醇）和端粒酶抑制剂（如 AZT）。本发明还提供了鉴定其他具有端粒损伤诱导活性和/或端粒酶抑制活性的制剂（以及具有这种活性的组合物）的方法，用于治疗癌症。
• US6995145B1
  申请人：——

  公开号：US6995145B1

  公开（公告）日：2006-02-07
• US7662361B2
  申请人：——

  公开号：US7662361B2

  公开（公告）日：2010-02-16
• [EN] METHODS AND COMPOSITIONS FOR MODULATING DRUG ACTIVITY THROUGH TELOMERE DAMAGE<br/>[FR] METHODES ET COMPOSITIONS DESTINEES A LA MODULATION DE L'ACTION DE MEDICAMENTS PAR DETERIORATION DE TELOMERES
  申请人：AU JESSIE L S

  公开号：WO2000074667A2

  公开（公告）日：2000-12-14

  The invention provides methods and compositions for modulating the activity of therapeutic agents for the treatment of a cancer by administering one or more agents that (either alone or in combination) induces telomere damage and inhibits telomerase activity in the cancer cell. The method initially uses, e.g., a telomere damage-inducing agent such as paclitaxel, and a telomerase inhibitory agent such as AZT. The invention also provides methods for identifying other agents with telomere damage-inducing activity and/or telomerase inhibitory activity (as well as and compositions having such activity), for use in the treatment of cancer.